About Amphasys
Amphasys is a company based in Lucerne (Switzerland) founded in 2012. Amphasys offers products and services including Single-Cell Analysis and Pollen Bioprocessing. Amphasys operates in a competitive market with competitors including 10X Genomics, Mission Bio, Cytek Biosciences, Cellares and LUMICKS, among others.
- Headquarter Lucerne, Switzerland
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website amphasys.com
- Social LinkedIn X Facebook YouTube
- Legal Name Amphasys Ag
- InvestorsMassChallenge
& 1 more
Products & Services of Amphasys
Amphasys offers a comprehensive portfolio of products and services, including Single-Cell Analysis and Pollen Bioprocessing.
Technology for detailed analysis of individual cells in bioprocessing.
Solutions for processing pollen in sustainable agricultural applications.
Apps and channels of Amphasys
its YouTube channel Amphasys has 163 subscribers and 30 videos.
Videos from Amphasys
The most watched videos on Amphasys's YouTube channel, Amphasys (163 subscribers). Click a video to play it here.
More on Amphasys.
Funding Insights of Amphasys
- Total Rounds 2
- First Round $108,566
(Jun 2013)
- Investors Count 2
All 2 funding rounds of Amphasys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | – | Grant | – | – | |
| Jun 2013 | $108,566 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Amphasys
Amphasys has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include MassChallenge and W.A. de Vigier Stiftung.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage entrepreneurs are accelerated through MassChallenge's program. | – | masschallenge.org | Boston, United States | |
Startup awards are provided to support Swiss entrepreneurs. | – | devigier.ch | Solothurn, Switzerland |
Investor details for Amphasys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Amphasys
3 dated milestones of Amphasys across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Amphasys is founded.
- Funding First funding round of $109K.
- Funding Latest funding round, Grant,.
Competitors of Amphasys
Amphasys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Cytek Biosciences, Cellares and LUMICKS, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| cytekbio.com | 2014 | San Francisco, United States | $132M | 676 | Advanced flow cytometry systems are manufactured for research applications. | |
| cellares.com | 2019 | San Francisco, United States | $355M | – | Medical devices for cell-based therapy manufacturing are produced. | |
| lumicks.com | 2014 | Amsterdam, Netherlands | $93.38M | – | Optical tweezers instruments for single-molecule analysis are manufactured. | |
| xcellbio.com | 2012 | San Francisco, United States | $40.9M | 11 | Cell culture analysis devices for cancer research are developed. | |
| levitasbio.com | 2017 | San Francisco, United States | $73.77M | – | Single-cell imaging platform developed via magnetic levitation technology. | |
| spherefluidics.com | 2010 | Cambridge, United Kingdom | $56.67M | 29 | Single-cell analysis systems are developed for biologics discovery. | |
| bionautlabs.com | 2015 | Los Angeles, United States | $63.2M | – | Miniature robots are developed for targeted drug delivery applications. |
Detailed competitors of Amphasys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Amphasys
10 companies that operate in the same segment as Amphasys (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Amphasys
Amphasys was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Amphasys is headquartered in Lucerne, Switzerland. It is registered at Lucerne, Lucerne, Switzerland.
Developer of label-free technology for pollen viability analysis. The company has designed a flow cytometer that contains a microfluidic chip and microelectrodes, that measure the electrical impedance when a cell passes through the applied electric field. This process uses AC whereas the Coulter principle involves the use of DC.
Amphasys's top competitors include 10X Genomics, Mission Bio and Cytek Biosciences.
Amphasys offers Single-Cell Analysis and Pollen Bioprocessing.
Amphasys has 2 investors. Key investors include MassChallenge, and W.A. de Vigier Stiftung.
Amphasys operates through Amphasys Ag.